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The prognostic and predictive value of del (17p)/TP53 mu-
tation in patients with chronic lymphocytic leukemia (CLL) 
is well established [1, 2]. An abnormality in TP53 indepen-
dently predicts rapid CLL progression and shorter survival, 
even in the era of novel agents. In addition, patients with 
TP53 abnormalities or 17p(del) demonstrate significantly 
decreased time to treatment initiation than those without 
TP53 aberration [3]. Although CLL patients with leukemia 
cells characterized by del(17p) and/or TP53 mutation 
have a poor prognosis when treated with fludarabine- 
-based chemotherapy [1], they do significantly better when 
treated with non-chemotherapeutic agents such as small 
molecule inhibitors of Bruton’s tyrosine kinase (BTK), 
phosphatidylinositol 3-kinase (PI3K), or B-cell lymphoma 
2 (BCL-2) inhibitors. Such TP53 abnormalities are now 
included in the IPI-CLL (International Prognostic Index for 
Chronic Lymphocytic Leukemia) prognostic model for CLL: 
patients with 17p deletion, TP53 mutation, or both, are 
considered to be at high risk [4].
For many years, the standard of care has been based 
on the detection of TP53 locus (17p deletion) by fluorescent 
in situ hybridization (FISH) [1]. As monoallelic mutations of 
TP53 equally affect treatment results, novel methods such 
as next-generation sequencing (NGS) and functional assays 
have been developed to improve detection of TP53 abnor-
malities. In several European countries, and in North Ame-
rica, molecular tests for TP53 abnormalities are routinely 
used as a part of CLL prognostication. Most Polish centers 
have only used the FISH method to identify TP53 locus re-
moval (i.e. 17p deletion); however, as monoallelic muta-
tions also have significant negative prognostic impact, it is 
also recommended to screen for both TP53 mutations and 
deletions. The most common approach to such screening 
is NGS, and this is the most convenient option for routine 
analysis. In addition, ultra-deep NGS permits the detection 
of minor clones with TP53 mutations, even below 1% [5].
Pepek et al. [6], in this issue of “Acta Haematologica 
Polonica”, report the results of a study examining the use 
of NGS in identifying TP53 mutations in relapsed and re-
fractory chronic lymphocytic leukemia (CLL) patients in 
Poland. The study was initiated by the Polish Adult Leuke-
mia Group (PALG) as an observational study and educa-
tional project aimed primarily at providing Polish hema-
tologists with the possibility of testing TP53 mutations 
by NGS. Additional objectives were to provide laboratory 
and clinical experience on TP53 mutations in CLL, and 
to identify subclonal TP53 mutations and other selected 
gene abnormalities which play a possible pathogenic and 
prognostic role in CLL.
TP53 abnormalities are less common in previously-un-
treated CLL patients than in relapsed or refractory patients. 
In addition, while no more than 5% of CLL patients are be-
lieved to carry the 17p deletion at diagnosis, it has been 
recorded in over 40% of patients with refractory CLL [7]. 
It is well established that TP53 mutation analysis should be 
performed in CLL patients before treatment initiation, and 
that patients with TP53 mutation should be considered for 
alternative treatment approaches. In the recent guidelines 
regarding the detection of tumor protein p53 expression, 
Eichhorst et al. [2] for the first time have recommended the 
use of FISH to identify chromosome 17 deletion [del(17p)]; 
if del(17p) is absent, TP53 sequencing should be perfor-
med to detect the presence of TP53 gene mutation. In such 
cases, it is recommended to test at least exons 4–10, but 
exons 2–11 should be evaluated. As additional genetic 
abnormalities can be acquired during the course of the 
disease, genetic analyses for del(17p)/TP53 mutations) 
should be repeated before the onset of any subsequent 
treatment in relapsed patients [8–10].
In conclusion, NGS analysis represents a sensitive and 
reproducible technique for the screening of TP53 gene mu-
tations, and should be performed routinely in CLL patients 
before each treatment initiation.
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